Gut resistome of NSCLC patients treated with immunotherapy
Rattachement africain : pl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background The newest method of treatment for patients with NSCLC (non-small cell lung cancer) is immunotherapy directed at the immune checkpoints PD-1 (Programmed Cell Death 1) and PD-L1 (Programmed Cell Death Ligand 1). PD-L1 is the only validated predictor factor for immunotherapy efficacy, but it is imperfect. Some patients do not benefit from immunotherapy and may develop primary or secondary resistance. This study aimed to assess the intestinal resistome composition of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors in the context of clinical features and potentially new prediction factors for assessing immunotherapy efficacy. Methods The study included 30 advanced NSCLC patients, 19 (57%) men and 11 (33%) women treated with first- or second-line immunotherapy (nivolumab, pembrolizumab or atezolizumab). We evaluated the patient’s gut resistome composition using the high sensitivity of targeted metagenomics. Results Studies have shown that resistome richness is associated with clinical and demographic factors of NSCLC patients treated with immunotherapy. Smoking seems to be associated with an increased abundance of macrolides, lincosamides, streptogramins and vancomycin core resistome. The resistome of patients with progression disease appears to be more abundant and diverse, with significantly higher levels of genomic markers of resistance to lincosamides (lnuC). The resistance genes lnuC, msrD, ermG, aph(6), fosA were correlated with progression-free survival or/and overall survival, thus may be considered as factors potentially impacting the disease. Conclusion The results indicate that the intestinal resistome of NSCLC patients with immune checkpoint inhibitors treatment differs depending on the response to immunotherapy, with several distinguished markers. Since it might impact treatment efficacy, it must be examined more deeply.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Gut resistome of NSCLC patients treated with immunotherapy
- Date Crossref
- 07/08/2024
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Veterinary Research Institute Department of Omics Analyses pays non établi dans la noticeStructure de recherche
-
Medical University of Lublin pays non établi dans la noticeUniversité ou école supérieure
-
University of Life Sciences in Lublin Department of Environmental Microbiology pays non établi dans la noticeUniversité ou école supérieure
-
Nicolaus Copernicus University pays non établi dans la noticeUniversité ou école supérieure
-
Medical University in Lublin Department of Pneumology pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Biological and Veterinary Sciences Department of Basic and Preclinical Sciences pays non établi dans la noticeUniversité ou école supérieure
Department of Omics Analyses — National Veterinary Research Institute, Medical University of Lublin et Department of Environmental Microbiology — University of Life Sciences in Lublin, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.